BioSight
Companies
Context Therapeutics Inc. logo

CNTX

NASDAQPHILADELPHIA, PA
Context Therapeutics Inc.

Context Therapeutics is a clinical-stage biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors in oncology. The company's lead programs are CTIM-76, a Claudin 6 by CD3 bispecific antibody currently in Phase 1 trials for gynecologic and testicular cancers; CT-95, a Mesothelin by CD3 bispecific antibody in Phase 1 development; and CT-202, a Nectin-4 by CD3 bispecific antibody designed with pH-dependent activation for the tumor microenvironment, expected to enter Phase 1 trials in the third quarter of 2026.

Price history not yet available for CNTX.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar